GlassScriptPhysician profile
Janice Dawn Morris
NPI 1194106237
$1,113.73
in general payments reported to CMS, 2019-2025
17 companies · $552 in 2025
The $552 reported for 2025 was more than what 75% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $99.00 · 2022: $166 · 2023: $212 · 2024: $84.28 · 2025: $552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $752 · Education: $96.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $751.95 |
| Education | $96.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $210.15 | 2022-2023 | |
| Janssen Biotech, INC. | $166.63 | 2022-2025 | Talvey, Tecvayli, Darzalex |
| Daiichi Sankyo INC. | $104.47 | 2024-2025 | Datroway, Injectafer |
| Pfizer INC. | $104.40 | 2024-2025 | |
| Incyte Corporation | $99.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $80.08 | 2022-2025 | |
| Stemline Therapeutics INC. | $79.15 | 2024-2025 | Orserdu |
| Pharmacosmos Therapeutics INC. | $68.28 | 2024-2025 | Monoferric |
| Merck Sharp & Dohme LLC | $39.62 | 2023 | Keytruda |
| Adaptive Biotechnologies Corporation | $28.98 | 2025 | Clonoseq |
| Alexion Pharmaceuticals, INC. | $27.06 | 2025 | Ultomiris |
| Agios Pharmaceuticals, INC. | $22.08 | 2025 | Pyrukynd |
| Gilead Sciences, INC. | $18.61 | 2025 | Trodelvy |
| Glaxosmithkline, LLC. | $18.56 | 2025 | Ojjaara |
| Lilly USA, LLC | $17.27 | 2025 | Verzenio, Jaypirca |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $15.06 | 2025 | |
| Novocure INC. | $14.33 | 2025 | Optune Lua (Novottf-200t) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janice Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.